Celularity Appoints Richard J. Berman to its Board of Directors
August 28 2024 - 4:45PM
Celularity Inc. (Nasdaq: CELU) (the “Company”), a regenerative and
cellular medicine company developing placental-derived allogeneic
cell therapies and advanced biomaterial products, announced today
the appointment of Richard J. Berman, to its Board of Directors.
Mr. Berman is an experienced public company director whose career
spans over 40 years of venture capital, senior management, and
merger and acquisitions experience. He has served as a director
and/or officer of over a dozen public and private companies in the
last five years, six of which have reached over one billion dollars
in market value. Previously, Mr. Berman worked at Goldman Sachs and
was Senior Vice President of Bankers Trust Company where he started
the M&A Leveraged Buyout Departments. He also has advised on
over $4 billion merger and acquisition transactions, completing
over 300 deals.
"I am pleased to welcome Richard Berman to the
Celularity Board of Directors, to which he brings a unique depth of
experience and leadership guiding public companies and helping them
build and execute growth plans,” said Robert J. Hariri, M.D.,
Ph.D., founder, Chairman and Chief Executive Officer of Celularity.
Mr. Berman commented on his new role, “I am pleased to join
Celularity at this key moment and look forward to working with Dr.
Hariri and his team as it executes the Company’s focused and
disciplined growth plan.”
About Celularity
Celularity Inc. (NASDAQ: CELU) is an innovative
regenerative and cellular medicine company. It is developing and
commercializing advanced biomaterial products and allogeneic,
cryopreserved, placental-derived cell therapies, all derived from
the postpartum placenta. What sets Celularity apart is its
therapeutic programs that target aging-related diseases, including
degenerative diseases, cancer, and immune disorders, using
mesenchymal-like adherent stromal cells (MLASCs), T-cells
engineered with CAR (CAR T-cells), and genetically modified and
unmodified natural killer (NK) cells. Celularity’s unique approach,
harnessing the placenta’s biology and ready availability, is paving
the way for therapeutic solutions that address significant unmet
unique biology and ready availability, it can develop therapeutic
solutions that address needs for effective, accessible, and
affordable therapies.
Investor Contact:Carlos RamirezSenior Vice
President, Celularity Inc.Carlos.ramirez@celularity.com
Media Contact:Raquel Cona / Michaela
FawcettKCSA Strategic Communicationsrcona@kcsa.com
/ mfawcett@kcsa.com
Celularity (NASDAQ:CELU)
Historical Stock Chart
From Aug 2024 to Sep 2024
Celularity (NASDAQ:CELU)
Historical Stock Chart
From Sep 2023 to Sep 2024